Intraocular pressure sensors, systems, and methods of use. Implantable intraocular pressure sensing devices that are hermetically sealed and adapted to wirelessly communicate with an external device. The implantable devices can include a hermetically sealed housing, the hermetically sealed housing including therein: an antenna in electrical communication with a rechargeable power source, the rechargeable power source in electrical communication with an ASIC, and the ASIC in electrical communication with a pressure sensor.

An endoleak preventing stent graft system, used for preventing the endoleaks except for type II endoleak, comprising: a metal mesh support layer fit for the shape of the artery blood vessel; a cover film layer covering on said metal mesh support layer; and a flexible mesh layer covering outside said cover film layer, said flexible mesh layer fills up the gap formed between said cover film layer and the inwall of said artery blood vessel under the effect of the flexibility of itself.

An endoleak preventing stent graft system, used for preventing the endoleaks except for type II endoleak, comprising: a metal mesh support layer fit for the shape of the artery blood vessel; a cover film layer covering on said metal mesh support layer; and a flexible mesh layer covering outside said cover film layer, said flexible mesh layer fills up the gap formed between said cover film layer and the inwall of said artery blood vessel under the effect of the flexibility of itself.

The present invention relates to novel compositions and methods for reducing or eliminating the thrombogenicity of a graft by modifying the graft with a cell-derived extracellular matrix lacking thrombospondin-2 (TSP2-null ECM) to render it non-thrombogenic when transplanted to a subject in need thereof. The invention also provides a method for improving the biocompatibility of a medical device or an implant by modifying the medical device or implant with a cell-derived TSP2-null ECM, whereby the medical device or implant is rendered non-thrombogenic and pro-migratory.

The present invention relates to novel compositions and methods for reducing or eliminating the thrombogenicity of a graft by modifying the graft with a cell-derived extracellular matrix lacking thrombospondin-2 (TSP2-null ECM) to render it non-thrombogenic when transplanted to a subject in need thereof. The invention also provides a method for improving the biocompatibility of a medical device or an implant by modifying the medical device or implant with a cell-derived TSP2-null ECM, whereby the medical device or implant is rendered non-thrombogenic and pro-migratory.

Drug eluting stents, methods of making, using, and verifying long-term stability of the drug eluting stents, and methods for predicting long term stent efficacy and patient safety after implantation of a drug eluting stent are disclosured. In one embodiment, a drug eluting stent may include a stent framework; a drug-containing layer; a drug embedded in the drug-containing layer; and a biocompatible base layer disposed over the stent framework and supporting the drug-containing layer. The drug-containing layer may have an uneven coating thickness. In addition or in alternative, the drug-containing layer may be configured to significantly dissolve/dissipate, disappear between 45 days and 60 days after stent implantation. Stents may reduce, minimize, or eliminate patient risks associated with the implantation of a stent, including, for example, restenosis, thrombosis, and or MACE.

Drug eluting stents, methods of making, using, and verifying long-term stability of the drug eluting stents, and methods for predicting long term stent efficacy and patient safety after implantation of a drug eluting stent are disclosured. In one embodiment, a drug eluting stent may include a stent framework; a drug-containing layer; a drug embedded in the drug-containing layer; and a biocompatible base layer disposed over the stent framework and supporting the drug-containing layer. The drug-containing layer may have an uneven coating thickness. In addition or in alternative, the drug-containing layer may be configured to significantly dissolve/dissipate, disappear between 45 days and 60 days after stent implantation. Stents may reduce, minimize, or eliminate patient risks associated with the implantation of a stent, including, for example, restenosis, thrombosis, and or MACE.

Disclosed is a composite hemocompatible material and a method for producing a composite hemocompatible material. The composite material includes a synthetic substrate and an animal biological tissue. The animal biological tissue is interlinked the synthetic substrate so as to bond the animal biological tissue to the synthetic substrate and form the composite hemocompatible material.

Disclosed is a composite hemocompatible material and a method for producing a composite hemocompatible material. The composite material includes a synthetic substrate and an animal biological tissue. The animal biological tissue is interlinked the synthetic substrate so as to bond the animal biological tissue to the synthetic substrate and form the composite hemocompatible material.

Engineered human tissue constructs are provided that are suitable for use in making humanized animals for use in pharmaceutical development. Humanized animals having the constructs implanted in vivo are provided. Methods of making and using the tissue-engineered constructs and humanized animals are also provided.